Table 1.

Chimeric antigen receptor T-cell clinical trials recruiting acute myeloid leukemia patients that have reported (initial) results

Study short title	Study identifier	Status	Phase	Condition	Interventional targets	Responsible party	Reference
Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33	NCT01864902	Unknowna	I/II	rrAML	CD33	Chinese PLA General Hospital, Beijing, China	Wang et al., 2015
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies	NCT03795779	Recruiting	Early phase 1	rrAML	CD33, CLL-1	iCell Gene Therapeutics, Stony Brook, New York, United States	Liu et al., 2018, 2020
Multiple CAR-T Cell Therapy Targeting AML	NCT04010877	Recruiting	I/II	rrAML	CD33, CLL-1, CD123	Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China	Zhang et al., 2020, 2021?
CD123 Redirected Autologous T Cells for AML	NCT02623582	Terminated	Early phase 1	rrAML	CD123	Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States	Cummins et al., 2017
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm	NCT02159495	Recruiting	I	prBPDCN, rrAML	CD123	City of Hope Medical Center, Duarte, California, United States	Budde et al., 2018
Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia	NCT04106076	Withdrawn	I	AML	CD123	Cellectis S.A., Paris, France	Cummins and Gill, 2019
Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/Refractory Acute Myeloid Leukemia	NCT03190278	Recruiting	I	rrAML	CD123	Cellectis S.A., Paris, France	Roboz et al., 2020
Safety Study of Anti Lewis Y Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome	NCT01716364	Unknowna	I	(rr)AML, MDS, MM	Lewis Y	Peter MacCallum Cancer Centre, Melbourne, Australia	Ritchie et al., 2013
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands	NCT02203825	Completed	I	AML, MDS-RAEB, MM	NKG2D Ligands	Celyad Oncology SA, New York, New York, United States	Baumeister et al., 2019
A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK)	NCT03018405	Unknowna	I/II	AML, CRC, EOC, FTC, MDS, MM, PC, TCC, TNBC	NKG2D Ligands	Celyad Oncology SA, New York, New York, United States	Sallman et al., 2018, 2019
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 (DEPLETHINK)	NCT03466320	Completed	I/II	AML, MDS	NKG2D Ligands	Celyad Oncology SA, New York, New York, United States	Sallman et al., 2020
EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2	NCT03612739	Withdrawn	I	AML	NKG2D ligands	Celyad Oncology SA, New York, New York, United States	Sallman et al., 2020
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02	NCT04167696	Recruiting	I	MDS, rrAML	NKG2D ligands	Celyad Oncology SA, New York, New York, United States	Deeren et al. 2020
Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies	NCT04230265	Recruiting	I	AML, B-ALL, BPDCN	CD123	CPT Cellex Patient Treatment GmbH, Dresden, Germany	Wermke et al., 2021

^aAs referenced on clinicaltrials.gov.

AML, acute myeloid leukemia; B-ALL, B-Cell Acute Lymphoblastic Leukemia; BPDCN, Blastic Plasmacytoid Dendritic-Cell Neoplasia; CRC, Colorectal Cancer; EOC, Epithelial Ovarian Cancer; FTC, Fallopial Tube Carcinoma; MDS, Myelodysplastic Syndrome; MM, Multiple Myeloma; PC, Prostate Cancer; RAEB, Refractory Anaemia with Excessive Blasts; rrAML, relapsed refractory AML; TCC, Transitional Cell Carcinoma; TNBC, Triple-Negative Breast Cancer.